Did DeStefano co-author studies with pharma-funded researchers?

Yes. DeStefano co-authored studies with researchers who had documented financial ties to the companies whose vaccines were being evaluated. For example, in a study assessing whether a GSK influenza vaccine could cause narcolepsy, his co-authors included individuals who received consultancy honoraria from GSK, research funding from GSK, Merck, Pfizer, Roche, and Sanofi Pasteur, and speaking and consulting fees from GSK and Sanofi.

What was the CDC Immunization Safety Office's budget under DeStefano?

The CDC's Immunization Safety Office had a budget of approximately $20 million, while the CDC spent over $8 billion purchasing vaccines from pharmaceutical companies. Aaron Siri argues this 400:1 ratio reveals that DeStefano's office was directed toward policy coordination with pharma rather than independent safety research during his 18-year tenure.

Did DeStefano work with vaccine safety advocates?

No. While DeStefano readily collaborated with pharmaceutical company insiders, he refused to engage with vaccine safety advocacy groups like ICAN that sought to hold companies accountable. This asymmetry — close working relationships with regulated companies but refusal to engage with public interest groups — is cited by Siri as evidence of operational-level regulatory capture.

Frank DeStefano — CDC MMR Study & Whistleblower

Q: Who is Frank DeStefano and what is the CDC whistleblower controversy?

Frank DeStefano headed the CDC's Immunization Safety Office from 2004 to 2022 and led the 2004 CDC study on MMR and autism. CDC senior scientist William Thompson later alleged that the study omitted statistically significant findings linking MMR timing to autism in a subgroup. DeStefano spent his 18-year tenure making policy decisions jointly with Merck, Sanofi, GSK, and Pfizer — the companies whose vaccines his office was supposed to independently evaluate.

Q: Did Frank DeStefano make vaccine safety policy jointly with pharmaceutical companies?

Yes. ICAN requested DeStefano's emails with Merck, Sanofi, GSK, and Pfizer. The CDC redacted large portions on the grounds that communications involved "setting CDC policy" — confirming DeStefano was making policy jointly with the companies he regulated. ICAN fought in federal court to lift these redactions, and unredacted portions revealed what Siri describes as DeStefano's "cozy relationship" with pharma companies.

Frank DeStefano is the CDC scientist who led the 2004 MMR-autism study that whistleblower William Thompson later alleged omitted statistically significant findings linking MMR timing to autism in a subgroup.

Frank DeStefano, MD, MPH is an epidemiologist who headed the CDC's Immunization Safety Office (ISO) from 2004 until 2022. According to Siri, rather than regulating vaccine makers, DeStefano spent his tenure making policy decisions collaboratively with the pharma companies whose products he was nominally responsible for overseeing.

Background

DeStefano holds an MD and MPH. He was the senior official at the CDC most directly responsible for vaccine safety monitoring during an 18-year tenure leading the ISO — the office with the largest explicit mandate to study and report on vaccine safety within the federal government.

Role in Vaccine Policy

Siri argues DeStefano's behavior exemplifies regulatory capture at the operational level. Key points:

Policy-Making with Pharma

ICAN, represented by Siri's firm, requested DeStefano's emails with Merck, Sanofi, GSK, and Pfizer. The CDC redacted large portions of these emails on the grounds that the communications involved setting CDC policy — a remarkable admission that DeStefano was making policy jointly with the companies he was supposed to regulate.

ICAN fought in federal court to lift these redactions. Siri writes that a review of the unredacted portions reveals "Dr. DeStefano's cozy relationship with these pharma companies."

Refusing to Work with Safety Advocates

Siri states that while DeStefano readily collaborated with pharma insiders, he refused to engage with vaccine safety advocacy groups like ICAN that sought to hold companies accountable.

Co-Authoring Studies with Conflicted Researchers

DeStefano co-authored studies with researchers who had documented financial ties to the companies whose vaccines were being evaluated. Siri provides an example: a study assessing whether a GSK influenza vaccine could cause narcolepsy, where DeStefano's co-authors included individuals who:

Conflicts of Interest / Affiliations

DeStefano's documented conflicts are indirect — he co-authored with pharma-funded researchers and made policy jointly with pharma companies — rather than direct personal financial relationships with vaccine makers.

Criticism and Controversy

Siri argues DeStefano's tenure is the clearest example of what happens when the head of a regulatory safety office prioritizes industry relationships over independent oversight: the ISO's $20 million budget was directed toward policy coordination with pharma rather than independent safety research.